Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 4
2(50.0%)
4Total
Phase 3(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07628985Phase 3Not Yet Recruiting

BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

Role: lead

NCT07622810Phase 3Not Yet Recruiting

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Role: lead

NCT07483645Active Not Recruiting

Effectiveness and Acceptability of LISEFEX® (Liposomal Iron With Vitamin C and Fiber) in People With Iron Deficiency Anemia.

Role: lead

NCT07417670Phase 4Completed

Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease

Role: lead

NCT06991348Phase 4Recruiting

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

Role: lead

All 5 trials loaded